Spoken Alpha
PRPH
ProPhase Labs, Inc.
Overview
ProPhase Labs provides genomic testing services, develops pharmaceutical compounds and diagnostic tests, and markets dietary supplements. Through subsidiaries Nebula Genomics and DNA Complete, the company offers whole genome sequencing and personalized health reports to consumers online and plans retail distribution.
ProPhase Labs, Inc is a Healthcare company operating in Diagnostics & Research with a $311,851 market cap.
Most recent reported earnings: Q2 FY2026 (Aug 19, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q3 FY2025Earnings2025-11-192 Q&A exchanges
- Q2 FY2025Earnings2025-08-206 Q&A exchanges
- Q1 FY2025Earnings2025-05-204 Q&A exchanges
- Q4 FY2024Earnings2025-03-311 Q&A exchange
- Q3 FY2024Earnings2024-11-134 Q&A exchanges
- Q2 FY2024Earnings2024-08-148 Q&A exchanges
- Q1 FY2024Earnings2024-05-094 Q&A exchanges
- Q4 FY2023Earnings2024-03-151 Q&A exchange
- Q3 FY2023Earnings2023-11-0921 Q&A exchanges
- Q2 FY2023Earnings2023-08-1217 Q&A exchanges
- Q1 FY2023Earnings2023-05-119 Q&A exchanges
- Q4 FY2022Earnings2023-03-2810 Q&A exchanges
- Q3 FY2022Earnings2022-11-109 Q&A exchanges
- Q2 FY2022Earnings2022-08-1113 Q&A exchanges
- Q1 FY2022Earnings2022-05-1319 Q&A exchanges
- Q4 FY2021Earnings2022-03-3017 Q&A exchanges
- Q3 FY2021Earnings2021-11-1212 Q&A exchanges
- Q2 FY2021Earnings2021-08-145 Q&A exchanges
- Q1 FY2021Earnings2021-05-136 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-19EPS$-0.22 vs ——Rev$1.0M vs ——EODHD
- Q1 FY20262026-03-31EPS$0.00 vs $-0.12+100.0%Rev$478.0K vs ——EODHD
- Q3 FY20252025-11-18EPS$-0.16 vs $-0.11-45.5%Rev$883.0K vs ——EODHD
- Q2 FY20252025-08-12EPS$-0.81 vs $-1.50+46.0%Rev$1.2M vs ——EODHD
- Q1 FY20252025-05-06EPS$-0.13 vs $-0.18+26.2%Rev$1.4M vs ——EODHD
- Q4 FY20242025-03-30EPS$-15.90 vs $-2.40-100.0%Rev$-2.5M vs ——EODHD
- Q3 FY20242024-11-12EPS$-3.50 vs $-3.10-12.9%Rev$3.1M vs ——EODHD
- Q2 FY20242024-08-13EPS$-3.30 vs $-2.45-34.7%Rev$2.5M vs ——EODHD
- Q1 FY20242024-05-08EPS$-0.70 vs $-2.80+75.0%Rev$3.6M vs ——EODHD
- Q4 FY20232024-03-14EPS$-0.51 vs $-0.26-96.2%Rev$3.5M vs ——EODHD
- Q3 FY20232023-11-08EPS$-3.00 vs $-1.95-53.8%Rev$8.4M vs ——EODHD
- Q2 FY20232023-08-09EPS$-2.00 vs $-1.40-42.9%Rev$13.2M vs ——EODHD
- Q1 FY20232023-05-10EPS$0.30 vs $-1.00+100.0%Rev$19.3M vs ——EODHD
- Q4 FY20222023-03-27EPS$-0.12 vs $0.03-100.0%Rev$21.8M vs ——EODHD
- Q3 FY20222022-11-09EPS$0.60 vs $1.90-68.4%Rev$24.2M vs ——EODHD
- Q2 FY20222022-08-10EPS$4.00 vs $1.60+100.0%Rev$29.1M vs ——EODHD
- Q1 FY20222022-05-12EPS$6.80 vs $4.70+44.7%Rev$47.5M vs ——EODHD
- Q4 FY20212022-03-29EPS$0.85 vs $0.44+93.2%Rev$45.2M vs ——EODHD
- Q3 FY20212021-11-11EPS$-1.49 vs $-2.40+37.9%Rev$9.5M vs ——EODHD
- Q2 FY20212021-08-12EPS$-0.90 vs $1.70-100.0%Rev$9.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-19 | $-0.22 | — | — | $1.0M | — | — | EODHD |
| Q1 FY2026 | 2026-03-31 | $0.00 | $-0.12 | +100.0% | $478.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-18 | $-0.16 | $-0.11 | -45.5% | $883.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.81 | $-1.50 | +46.0% | $1.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.13 | $-0.18 | +26.2% | $1.4M | — | — | EODHD |
| Q4 FY2024 | 2025-03-30 | $-15.90 | $-2.40 | -100.0% | $-2.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-3.50 | $-3.10 | -12.9% | $3.1M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-3.30 | $-2.45 | -34.7% | $2.5M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.70 | $-2.80 | +75.0% | $3.6M | — | — | EODHD |
| Q4 FY2023 | 2024-03-14 | $-0.51 | $-0.26 | -96.2% | $3.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-3.00 | $-1.95 | -53.8% | $8.4M | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-2.00 | $-1.40 | -42.9% | $13.2M | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $0.30 | $-1.00 | +100.0% | $19.3M | — | — | EODHD |
| Q4 FY2022 | 2023-03-27 | $-0.12 | $0.03 | -100.0% | $21.8M | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $0.60 | $1.90 | -68.4% | $24.2M | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $4.00 | $1.60 | +100.0% | $29.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $6.80 | $4.70 | +44.7% | $47.5M | — | — | EODHD |
| Q4 FY2021 | 2022-03-29 | $0.85 | $0.44 | +93.2% | $45.2M | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-1.49 | $-2.40 | +37.9% | $9.5M | — | — | EODHD |
| Q2 FY2021 | 2021-08-12 | $-0.90 | $1.70 | -100.0% | $9.1M | — | — | EODHD |
Source: EODHD. PRPH reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PRPH.
$ curl https://api.spokenalpha.com/v1/companies/PRPHFAQ
Frequently asked about PRPH
Where can I find ProPhase Labs, Inc.'s (PRPH) earnings call transcripts?
Spoken Alpha indexes PRPH's earnings call transcripts at https://spokenalpha.com/companies/PRPH. Each call links to attributed speakers and parsed analyst Q&A. ProPhase Labs, Inc.'s own investor relations page is at https://ir.prophaselabs.com/.
When was ProPhase Labs, Inc.'s most recent earnings call?
ProPhase Labs, Inc. (PRPH) held its most recent earnings call on 2025-11-19, covering fiscal Q3 2025.
What sector is PRPH in?
ProPhase Labs, Inc. (PRPH) operates in the Healthcare sector (Diagnostics & Research industry).